Treatment(s) already received-Biological therapy Posts on Medivizor
Navigation Menu

Treatment(s) already received-Biological therapy Posts on Medivizor

Searching for patients with chronic myeloid leukemia to try a new combination of targeted treatments.

Posted by on Jun 29, 2019 in Leukemia | 0 comments

In a nutshell This study is searching for patients with chronic myeloid leukemia (CML) to try a new drug ruxolitinib (NSC-752295) with BCR-ABL Tyrosine Kinase Inhibitors. The main outcome that will be measured is the rate of significant reduction of the BCR-ABL marker. This trial is recruiting across the United States. The details BCR-ABL is a protein...

Read More

Managing side effects of ibrutinib treatment

Posted by on Jun 23, 2019 in Leukemia | 0 comments

In a nutshell This study summarised the side effects of ibrutinib (Imbruvica) and how to manage them.  Some background Ibrutinib is an FDA approved drug used to treat lymphoma and leukemia. It works on the immune cells in the body which may lead to many side effects. These include diarrhea, upper respiratory infections, bleeding, tiredness,...

Read More

Searching for patients with advanced non-small cell lung cancer to test a new T-cell treatment

Posted by on May 26, 2019 in Lung cancer | 0 comments

In a nutshell This phase 2 trial will investigate the effectiveness of genetically-engineered cell treatment (GECT) in advanced cancer.  The main outcome will be the response to treatment. This trial is recruiting at the National Cancer Institute, Maryland, US.  The details There are limited treatment options for advanced cancer. One...

Read More

Looking for patients with non-small cell lung cancer to test a new immunotherapy combination

Posted by on May 26, 2019 in Lung cancer | 0 comments

In a nutshell This phase 2 trial will investigate the safety and effectiveness of different treatment combinations containing durvalumab (Imfinzi) in non-small cell lung cancer (NSCLC). The main outcome will be the objective response rate (ORR). The details Non-small cell lung cancer (NSCLC) is a common form of lung cancer. It is often diagnosed at...

Read More

Looking for patients advanced colorectal cancer to test a new treatment and a predictive blood test

Posted by on Apr 17, 2019 in Colorectal cancer | 0 comments

In a nutshell This trial is examining the effectiveness of circulating cell-free tumor DNA (cCFTD) as a predictive factor for the treatment of advanced colorectal cancer with regorafenib (Stivarga) or TAS-102. The main outcome to be measured will be to evaluate the ability of early change of cCFTD after the start of the treatment. This trial will be...

Read More

Effectiveness of venetoclax in patients with unresponsive chronic lymphocytic leukemia

Posted by on Mar 9, 2019 in Leukemia | 0 comments

In a nutshell This study looked at the effectiveness of venetoclax (Venclexta) in the treatment of relapsed or unresponsive chronic lymphocytic leukemia (CLL). Researchers found venetoclax improved outcomes in these patients. Some background CLL is a cancer of the bone marrow. This may lead to an abnormal immune system. It is also often...

Read More

Searching for patients with advanced breast cancer to trial a new medication

Posted by on Jan 8, 2019 in Breast cancer | 0 comments

In a nutshell This trial is aiming to determine how effective a new medication called elacestrant is for treating advanced breast cancer. The main outcome that will be measured is how long the patients go without the disease progressing. This study is being conducted in Illinois, United States. The details Some breast cancers grow in response to the...

Read More

Re-treatment with cetuximab improves cancer outcomes in patients with inoperable colorectal cancer

Posted by on Dec 23, 2018 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effect of cetuximab (Erbitux) in patients with metastatic (spread to other parts of the body) colorectal cancer who did not respond to initial cetuximab treatment. Researchers suggested that this treatment may be beneficial in longer treatment durations. Some background The standard treatment for patients...

Read More

Comparing targeted therapy to chemotherapy for patients with advanced NSCLC

Posted by on Aug 8, 2018 in Lung cancer | 0 comments

In a nutshell This trial compared the effectiveness of alectinib (Alecensa) against chemotherapy for treating patients with ALK-positive non-small-cell lung cancer that have progressed passed previous targeted therapy. The authors determined that alectinib was more effective than chemotherapy at treating this subgroup of patients. Some background Lung...

Read More